Mp70-03 Racial Disparities in the Treatment of Depression in Patients With Prostate Cancer on Androgen Deprivation Therapy

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70)1 May 2024MP70-03 RACIAL DISPARITIES IN THE TREATMENT OF DEPRESSION IN PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY Rishabh K. Simhal, Asher Mandel, Kerith R. Wang, Yash B. Shah, and Mihir S. Shah Rishabh K. SimhalRishabh K. Simhal , Asher MandelAsher Mandel , Kerith R. WangKerith R. Wang , Yash B. ShahYash B. Shah , and Mihir S. ShahMihir S. Shah View All Author Informationhttps://doi.org/10.1097/01.JU.0001008796.84999.75.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Androgen deprivation therapy (ADT) is a key treatment option for many patients with prostate cancer (PCa). However, this hormonal therapy confers physical and psychological morbidities, with a common side effect being major depressive disorder. We aim to analyze potential racial disparities in the diagnosis and management of depression associated with ADT. METHODS: TriNetX health record network was queried for PCa patients treated with ADT from 2003-2023. Differences in rates of depression diagnosis and treatment were compared between White and Black patients. Means, odds ratios, and t-tests were calculated in univariate analysis with 95% confidence intervals. RESULTS: Data queried from 93 healthcare organizations yielded 78,313 PCa patients treated with ADT. Patients on ADT had 60% greater odds of developing depression versus other patients [9% vs 6%; OR 1.6; 95% CI (1.5-1.7); p<0.0001]. Of those with depression secondary to ADT, only 35% were treated with antidepressants. After starting ADT, White patients had 30% greater odds of being diagnosed with depression, compared to Black patients [10% vs 8%; OR 1.3; 95% CI (1.2-1.4); p<0.001] (Table 1). White patients also had higher odds of being treated with a first line antidepressant than Black patients [56% vs 48%; OR 1.4, 95% CI (1.2-1.6), p<0.001]. CONCLUSIONS: This analysis confirms a significant association between ADT and the development of clinical depression and highlights its medical undertreatment. Importantly, our findings also indicate significant racial disparities in the identification and treatment of depression. Routine screening initiatives that account for social determinants of health may alleviate this disparity. Limitations of this study include its retrospective design and lack of data describing severity of depression, which might correlate with need for medication. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1129 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Rishabh K. Simhal More articles by this author Asher Mandel More articles by this author Kerith R. Wang More articles by this author Yash B. Shah More articles by this author Mihir S. Shah More articles by this author Expand All Advertisement PDF downloadLoading ...